Jan 27, 2020/by 3mediawebEpygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies
Jul 29, 2019/by 3mediawebEpygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome
Jun 24, 2019/by 3mediawebEpygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome
Aug 23, 2017/by 3mediawebEpygenix Therapeutics Receives US FDA Orphan Drug Designation For EPX-300 For The Treatment Of Patients With Dravet Syndrome.
Jun 8, 2017/by 3mediawebProfile of Epygenix Therapeutics is listed in June 2017 issue of Biopharma Dealmakers – Published in Nature Reviews Drug Discovery & Nature Biotechnology
Apr 25, 2017/by 3mediawebEpygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome
Apr 21, 2017/by 3mediaweb“Discovering & Developing Drugs for Genetic Epilepsies” highlighted in the April 2017 issue of GHP (UK Pharma Journal)
Feb 10, 2017/by Lysa MillerEpilepsy drug discovered in fish model shows promise in small pediatric clinical trial
